How big is Mirum Pharmaceuticals, Inc.?

As of Jun 18, Mirum Pharmaceuticals, Inc. has a market capitalization of $2.51 billion, with net sales of $379.25 million and a net profit of -$77.34 million over the latest four quarters. The company's balance sheet shows shareholder's funds of $225.64 million and total assets of $670.75 million.

As of Jun 18, Mirum Pharmaceuticals, Inc. has a market capitalization of 2,511.41 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 379.25 million for the latest four quarters. During the same period, it recorded a net profit of -77.34 million.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 225.64 million and total assets amounting to 670.75 million.

What does Mirum Pharmaceuticals, Inc. do?

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for liver diseases. As of March 2025, it reported net sales of $112 million and a net loss of $15 million, with a market cap of approximately $2.51 billion.

Overview: <BR>Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for debilitating liver diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 112 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,511.41 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.14 <BR>Return on Equity: -33.16% <BR>Price to Book: 10.77 <BR><BR>Contact Details: <BR>Address: 950 Tower Ln Ste 1050, FOSTER CITY CA: 94404-4251 <BR>Tel: 1 650 6674085 <BR>Fax: 1 302 2693855 <BR>Website: https://mirumpharma.com/

Should I buy, sell or hold Mirum Pharmaceuticals, Inc.?

Who are in the management team of Mirum Pharmaceuticals, Inc.?

As of March 2022, the management team of Mirum Pharmaceuticals, Inc. includes Chairman Michael Grey, CEO Christopher Peetz, and several independent directors: Tiba Aynechi, Laura Brege, Laurent Fischer, Patrick Heron, and Edward Mathers.

As of March 2022, the management team of Mirum Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Michael Grey, Chairman of the Board<BR>- Mr. Christopher Peetz, President, Chief Executive Officer, and Director<BR>- Dr. Tiba Aynechi, Director<BR>- Ms. Laura Brege, Independent Director<BR>- Dr. Laurent Fischer, Independent Director<BR>- Mr. Patrick Heron, Independent Director<BR>- Mr. Edward Mathers, Independent Director<BR><BR>In summary, the management team consists of a mix of directors, including the Chairman, CEO, and several independent directors.

Is Mirum Pharmaceuticals, Inc. overvalued or undervalued?

As of August 5, 2021, Mirum Pharmaceuticals, Inc. is considered risky and overvalued with a Price to Book Value of 9.85 and an EV to Sales ratio of 6.14, despite strong stock performance, as indicated by a year-to-date return of 82.15% compared to the S&P 500's 12.22%.

As of 5 August 2021, the valuation grade for Mirum Pharmaceuticals, Inc. moved from does not qualify to risky. Based on the available metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 9.85, an EV to Sales ratio of 6.14, and a ROE of -33.16%. In comparison to peers, TG Therapeutics, Inc. has a P/E of 83.91, while Catalyst Pharmaceuticals, Inc. shows a much more attractive P/E of 12.14, highlighting the relative overvaluation of Mirum.<BR><BR>Despite the overvaluation, Mirum has shown strong stock performance, with a year-to-date return of 82.15%, significantly outperforming the S&P 500's 12.22% return in the same period. However, the negative profitability metrics and high valuation ratios suggest caution for potential investors.

Is Mirum Pharmaceuticals, Inc. technically bullish or bearish?

As of June 18, 2025, Mirum Pharmaceuticals is in a bullish trend supported by strong technical indicators, despite mixed signals from the RSI, and has significantly outperformed the S&P 500 with year-to-date and one-year returns of 82.15% and 98.73%, respectively.

As of 18 June 2025, the technical trend for Mirum Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and moving averages are bullish on the daily time frame. Additionally, Bollinger Bands, KST, Dow Theory, and OBV all indicate bullish trends on both weekly and monthly periods. However, the RSI shows bearish signals on both weekly and monthly time frames, suggesting some caution.<BR><BR>In terms of performance, Mirum Pharmaceuticals has significantly outperformed the S&P 500 over various periods, with a year-to-date return of 82.15% compared to the S&P 500's 12.22%, and a 1-year return of 98.73% versus 17.14%. Overall, the technical indicators suggest a strong bullish stance despite some mixed signals from the RSI.